- Home
- COEP vs ANTX Comparison
COEP vs ANTX Comparison
Compare COEP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ANTX
- Stock Information
- Founded
- COEP 2017
- ANTX 2017
- Country
- COEP United States
- ANTX United States
- Employees
- COEP N/A
- ANTX N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ANTX Health Care
- Exchange
- COEP Nasdaq
- ANTX Nasdaq
- Market Cap
- COEP 27.4M
- ANTX 33.2M
- IPO Year
- COEP N/A
- ANTX 2022
- Fundamental
- Price
- COEP $11.26
- ANTX $1.10
- Analyst Decision
- COEP
- ANTX Buy
- Analyst Count
- COEP 0
- ANTX 2
- Target Price
- COEP N/A
- ANTX $2.00
- AVG Volume (30 Days)
- COEP 38.9K
- ANTX 95.4K
- Earning Date
- COEP 08-15-2025
- ANTX 08-12-2025
- Dividend Yield
- COEP N/A
- ANTX N/A
- EPS Growth
- COEP N/A
- ANTX N/A
- EPS
- COEP N/A
- ANTX N/A
- Revenue
- COEP $62,874.00
- ANTX N/A
- Revenue This Year
- COEP N/A
- ANTX N/A
- Revenue Next Year
- COEP N/A
- ANTX N/A
- P/E Ratio
- COEP N/A
- ANTX N/A
- Revenue Growth
- COEP N/A
- ANTX N/A
- 52 Week Low
- COEP $2.31
- ANTX $0.87
- 52 Week High
- COEP $13.70
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- COEP 74.07
- ANTX 48.42
- Support Level
- COEP $7.25
- ANTX $1.05
- Resistance Level
- COEP $10.00
- ANTX $1.10
- Average True Range (ATR)
- COEP 0.66
- ANTX 0.04
- MACD
- COEP 0.36
- ANTX 0.00
- Stochastic Oscillator
- COEP 90.20
- ANTX 50.00
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.